Differential pathogenesis of cowpox virus intranasal infections in mice induced by low and high inoculum volumes and effects of cidofovir treatment

International Journal of Antimicrobial Agents

Volumn 31, Issue 4, 2008, Pages 352-359

  Smee, Donald F ^a   Gowen, Brian B ^a   Wandersee, Miles K ^a   Wong, Min Hui ^a   Skirpstunas, Ramona T ^a   Baldwin, Thomas J ^a   Hoopes, Justin D ^a   Sidwell, Robert W ^a  

^a UTAH STATE UNIVERSITY   (United States)

Author keywords

Antiviral; Chemokines; Cidofovir; Cowpox; Cytokines; Orthopoxvirus

Indexed keywords

CHEMOKINE; CIDOFOVIR; CYTOKINE; INTERLEUKIN 6;

ANIMAL CELL; ANIMAL EXPERIMENT; ANIMAL MODEL; ANIMAL TISSUE; ARTICLE; CONTROLLED STUDY; COWPOX VIRUS; CYTOKINE PRODUCTION; FEMALE; HEPATITIS; INOCULATION; LOWER RESPIRATORY TRACT; LUNG; MOUSE; NONHUMAN; NOSE; PATHOGENESIS; PNEUMONIA; PRIORITY JOURNAL; SURVIVAL; SYNCYTIUM; UPPER RESPIRATORY TRACT; VIRUS REPLICATION;

ADMINISTRATION, INTRANASAL; ANIMALS; ANTIVIRAL AGENTS; BODY WEIGHT; CHEMOKINES; COWPOX; COWPOX VIRUS; CYTOKINES; CYTOSINE; FEMALE; GIANT CELLS; LUNG; MICE; MICE, INBRED BALB C; ORGAN SIZE; PHOSPHONIC ACIDS;

EID: 40849142254     PISSN: 09248579     EISSN: None     Source Type: Journal    
DOI: 10.1016/j.ijantimicag.2007.11.013     Document Type: Article

References (16)

1. Bray M., Martinez M., Smee D.F., Kefauver D., Thompson E., and Huggins J.W. Cidofovir protects mice against lethal aerosol or intranasal cowpox virus challenge. J. Infect Dis 181 (2000) 10-19
2. Smee D.F., and Sidwell R.W. A review of compounds exhibiting anti-orthopoxvirus activity in animal models. Antiviral Res 57 (2003) 41-52
3. Martinez M.J., Bray M.P., and Huggins J.W. A mouse model of aerosol-transmitted orthopoxviral disease: morphology of experimental aerosol-transmitted orthopoxviral disease in a cowpox virus-BALB/c mouse system. Arch Pathol Lab Med 124 (2000) 362-377
4. Smee D.F., Bailey K.W., and Sidwell R.W. Treatment of lethal vaccinia virus respiratory infections in mice with cidofovir. Antivir Chem Chemother 12 (2001) 71-76
5. Quenelle D.C., Collins D.J., and Kern E.R. Efficacy of multiple- or single-dose cidofovir against vaccinia and cowpox virus infections in mice. Antimicrob Agents Chemother 47 (2003) 3275-3280
6. Quenelle D.C., Collins D.J., Wan W.B., Beadle J.R., Hostetler K.Y., and Kern E.R. Oral treatment of cowpox and vaccinia virus infections in mice with ether lipid esters of cidofovir. Antimicrob Agents Chemother 48 (2004) 404-412
7. Knorr C.W., Allen S.D., Torres A.R., and Smee D.F. Effects of cidofovir treatment on cytokine induction in murine models of cowpox and vaccinia virus infection. Antiviral Res 72 (2006) 125-133
8. Smee D.F., Sidwell R.W., Kefauver D., Bray M., and Huggins J.W. Characterization of wild-type and cidofovir-resistant strains of camelpox, cowpox, monkeypox, and vaccinia viruses. Antimicrob Agents Chemother 46 (2002) 1329-1335
9. Smee D.F., Wandersee M.K., Bailey K.W., Wong M.-H., Chu C.K., Gadthula S., et al. Cell line dependency for antiviral activity and in vivo efficacy of N-methanocarbathymidine against orthopoxvirus infections in mice. Antiviral Res 73 (2007) 69-77
10. Sládková T., and Kostolanský F. The role of cytokines in the immune response to influenza A virus infection. Acta Virol 50 (2006) 151-162
11. Pfeffer K. Biological functions of tumor necrosis factor cytokines and their receptors. Cytokine Growth Factor Rev 14 (2003) 185-191
12. Wachsman M., Petty B.G., Cundy K.C., Jaffe H.S., Fisher P.E., Pastelak A., et al. Pharmacokinetics, safety and bioavailability of HPMPC (cidofovir) in human immunodeficiency virus-infected subjects. Antiviral Res 29 (1996) 153-161
13. Neyts J., and De Clercq E. Efficacy of (S)-1-(3-hydroxy-2-phosphonylmethoxypropyl)cytosine for the treatment of lethal vaccinia virus infections in severe combined immune deficiency (SCID) mice. J Med Virol 41 (1993) 242-246
14. Ramshaw I.A., Ramsay A.J., Karupiah G., Rolph M.S., Mahalingam S., and Ruby J.C. Cytokines and immunity to viral infections. Immunol Rev 159 (1997) 119-135
15. Geisbert T.W., and Jahrling P.B. Exotic emerging viral diseases: progress and challenges. Nat Med 10 12 Suppl. (2004) S110-S121
16. Gowen B.B., Hoopes J.D., Wong M.H., Jung K.H., Isakson K.C., Alexopoulou L., et al. TLR3 deletion limits mortality and disease severity due to Phlebovirus infection. J. Immunol 177 (2006) 6301-6307